OTX-101 0.05% + OTX-101 0.09% + Vehicle

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca, Dry Eye Disease

Trial Timeline

Sep 1, 2014 → May 1, 2015

NCT ID

NCT02254265

About OTX-101 0.05% + OTX-101 0.09% + Vehicle

OTX-101 0.05% + OTX-101 0.09% + Vehicle is a phase 2/3 stage product being developed by Sun Pharmaceutical for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT02254265. Target conditions include Keratoconjunctivitis Sicca, Dry Eye Disease.

What happened to similar drugs?

1 of 9 similar drugs in Keratoconjunctivitis Sicca were approved

Approved (1) Terminated (0) Active (8)

✅Cyclosporine A + DexamethasoneNovartisApproved

🔄FK506Astellas PharmaPhase 3

🔄FK506 + placeboAstellas PharmaPhase 3

🔄OTX-101 0.09%Sun PharmaceuticalPhase 3

🔄cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3

🔄INS365 Ophthalmic SolutionMerckPhase 3

🔄RebamipideNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02254265	Phase 2/3	Completed	Sep 1, 2014	May 1, 2015	Keratoconjunctivitis Sicca

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors

Product	Company	Stage	Hype Score
FK506	Astellas Pharma	Phase 3	40
FK506 + placebo	Astellas Pharma	Phase 3	40
OTX-101 0.09%	Sun Pharmaceutical	Phase 3	40
cyclosporine + vehicle of OTX-101	Sun Pharmaceutical	Phase 3	40
INS365 Ophthalmic Solution	Merck	Phase 3	40
Pimecrolimus + Vehicle	Novartis	Phase 2	35
Cyclosporine A + Dexamethasone	Novartis	Approved	43
Rebamipide	Novartis	Phase 3	40
Rebamipide	Novartis	Phase 3	40
Tasocitinib + Tasocitinib + vehicle for Tasocitinib	Pfizer	Phase 2	27
Dupilumab	Regeneron Pharmaceuticals	Phase 2	31
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo	Rigel Pharmaceuticals	Phase 1	23
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo	Rigel Pharmaceuticals	Phase 2	29
CF101	Can Fite Biopharma	Phase 3	30
CF101 + Placebo	Can Fite Biopharma	Phase 2	25